Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 3-4/2012

01.12.2012

Genomics screens for metastasis genes

verfasst von: Jinchun Yan, Qihong Huang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2012

Einloggen, um Zugang zu erhalten

Abstract

Metastasis is responsible for most cancer mortality. The process of metastasis is complex, requiring the coordinated expression and fine regulation of many genes in multiple pathways in both the tumor and host tissues. Identification and characterization of the genetic programs that regulate metastasis is critical to understanding the metastatic process and discovering molecular targets for the prevention and treatment of metastasis. Genomic approaches and functional genomic analyses can systemically discover metastasis genes. In this review, we summarize the genetic tools and methods that have been used to identify and characterize the genes that play critical roles in metastasis.
Literatur
1.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nature Reviews Cancer, 3, 1–6.
2.
Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571–573.
3.
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277–300.
4.
Chambers, A. F., Naumov, G. N., Vantyghem, S. A., & Tuck, A. B. (2000). Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Research, 2, 400–407.PubMed
5.
Parker, B. S., & Sukumar, S. (2003). Distant metastasis in breast cancer. Cancer Biology & Therapy, 2, 14–16.
6.
Gupta, G. P., & Massague, J. (2006). Cancer metastasis: building a framework. Cell, 127, 679–695.PubMed
7.
Steeg, P. S. (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine, 12, 895–904.PubMed
8.
Welch, D. R., Steeg, P. S., & Rinker-Schaeffer, C. W. (2000). Molecular biology of breast cancer metastasis: genetic regulation of human breast carcinoma metastasis. Breast Cancer Research, 2(6), 408–416.PubMed
9.
Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584–593.PubMed
10.
Yokota, J. (2000). Tumor progression and metastasis. Carcinogenesis, 21, 497–503.PubMed
11.
Hurst, D. R., & Welch, D. R. (2011). Metastasis suppressor genes: at the interface between the environment and tumor cell growth. International Review of Cell and Molecular Biology, 286, 107–180.PubMed
12.
Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275–292.PubMed
13.
Weiss, L. (1990). Metastasis inefficiency. Advances in Cancer Research, 54, 159–211.PubMed
14.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegu, E., & Zlotnik, A. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50–56.PubMed
15.
Leone, A., Flatow, U., King, C. R., Sandeen, M. A., Margulies, I. M. K., Liotta, L. A., & Steeg, P. S. (1991). Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65, 25–35.PubMed
16.
Seraj, M. J., Samant, R. S., Verderame, M. F., & Welch, D. R. (2000). Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Research, 60, 2764–2769.PubMed
17.
Lee, J., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., & Welch, D. R. (1996). Kiss-1, a novel human malignant melanoma metastasis-suppressor gene. Journal of the National Cancer Institute, 88, 1731–1737.PubMed
18.
Steeg, P. S. (2003). Metastasis suppressors alter the signal transduction of cancer cells. Nature Reviews Cancer, 3, 55–63.PubMed
19.
Eccles, S. A., & Welch, D. R. (2007). Metastasis: recent discoveries and novel treatment. Lancet, 369, 1742–1757.PubMed
20.
Kendal, W. S., Wang, R. Y., Hsu, T. C., & Frost, P. (1987). Rate of generation of major karyotypic abnormalities in relationship to the metastatic potential of B16 murine melanoma. Cancer Research, 47(14), 3835–3841.PubMed
21.
Kalebic, T., Williams, J. E., Talmadge, J. E., Kao-Shan, C. S., Kravitz, B., Locklear, K., Siegal, G. P., Liotta, L. A., Sobel, M. E., & Steeg, P. S. (1987). A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity. Clinical & Experimental Metastasis, 6(4), 301–318.
22.
Pettaway, C. A., Pathak, S., Greene, G., Ramirez, E., Wilson, M. R., Killion, J. J., & Fidler, I. J. (1996). Selection of highly metastatic variants of different human prostatic carcinoma using orthotopic implantation in nude mice. Clinical Cancer Research, 2(9), 1627–1636.PubMed
23.
Emerson, J. C., Salmon, S. E., Dalton, W., McGee, D. L., Yang, J. M., Thompson, F. H., & Trent, J. M. (1993). Cytogenetics and clinical correlations in breast cancer. Advances in Experimental Medicine and Biology, 330, 107–118.PubMed
24.
Adeyinka, A., Pandis, N., Nilsson, J., Idvall, I., Mertens, F., Petersson, C., Heim, S., & Mitelman, F. (1996). Different cytogenetic patterns in skeletal breast cancer metastases. Genes, Chromosomes & Cancer, 16(1), 72–74.
25.
Adeyinka, A., Kytola, S., Mertens, F., Pandis, N., & Larsson, C. (2000). Spectral karyotyping and chromosome banding studies of primary breast carcinoma and their lymph node metastases. International Journal of Molecular Medicine, 5(3), 235–240.PubMed
26.
Dracopoli, N. C., Alhadeff, B., Houghton, A. N., & Old, L. J. (1987). Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Research, 47(15), 3995–4000.PubMed
27.
Winqvist, R., Hampton, G. M., Mannermaa, A., Blanco, G., Alavaikko, M., Kiviniemi, H., Taskinen, P. J., Evans, G. A., Wright, F. A., Newsham, I., & Cavenee, W. K. (1995). Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Research, 55(12), 2660–2664.PubMed
28.
Fournier, R. E., & Ruddle, F. H. (1977). Microcell-mediated transfer of murine chromosomes into mouse, Chinese hamster, and human somatic cells. Proceedings of the National Academy of Sciences of the United States of America, 74, 319–323.PubMed
29.
Yoshida, B. A., Sokoloff, M. M., Welch, D. R., & Rinker-Schaeffer, C. W. (2000). Metastasis-suppressor genes: a review and perspective on an emerging field. Journal of the National Cancer Institute, 92(21), 1717–1730.PubMed
30.
Ichikawa, T., Ichikawa, Y., & Isaacs, J. T. (1991). Genetic factors and suppression of metastatic ability of prostate cancer. Cancer Research, 51, 3788–3792.PubMed
31.
Chekmareva, M. A., Hollowell, C. M., Smith, R. C., Davis, E. M., LeBeau, M. M., & Rinker-Schaeffer, C. W. (1997). Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate, 33, 271–280.PubMed
32.
Luu, H. H., Zagaja, G. P., Dubauskas, Z., Chen, S. L., Smith, R. C., Watabe, K., et al. (1998). Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Research, 58, 3561–3565.PubMed
33.
Matsuda, T., Sasaki, M., Kato, H., Yamada, H., Cohen, M., Barrett, J. C., et al. (1997). Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma. Oncogene, 15, 2773–2781.PubMed
34.
Miele, M. E., Robertson, G., Lee, J. H., Coleman, A., McGary, C. T., Fisher, P. B., et al. (1996). Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosome 1 or 6. Molecular Carcinogenesis, 15, 284–299.PubMed
35.
You, J., Miele, M. E., Dong, C., & Welch, D. R. (1995). Suppression of human melanoma metastasis by introduction of chromosome 6 may be partially due to inhibition of motility, but not to inhibition of invasion. Biochemical and Biophysical Research Communication, 208, 476–484.
36.
Miele, M. E., De La Rosa, A., Lee, J. H., Hicks, D. J., Dennis, J. W., Steeg, P. S., et al. (1997). Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23). Clinical & Experimental Metastasis, 15, 259–265.
37.
Phillips, K. K., Welch, D. R., Miele, M. E., Lee, J. H., Wei, L. L., & Weissman, B. E. (1996). Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Research, 56, 1222–1227.PubMed
38.
Nihei, N., Ichikawa, T., Kawana, Y., Kuramochi, H., Kugoh, H., Oshimura, M., et al. (1996). Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer. Genes, Chromosomes & Cancer, 17, 260–268.
39.
Kuramochi, H., Ichikawa, T., Nihei, N., Kawana, Y., Suzuki, H., Schalken, J. A., et al. (1997). Suppression of invasive ability of highly metastatic rat prostate cancer by Introduction of human chromosome 8. Prostate, 31, 14–20.PubMed
40.
Nihei, N., Ichikawa, T., Kawana, Y., Kuramochi, H., Kugo, Oshimura, M., et al. (1995). Localization of metastasis suppressor gene(s) for rat prostate cancer to the long arm of human chromosome 10. Genes, Chromosomes & Cancer, 14, 112–119.
41.
Rinker-Schaeffer, C. W., Hawkins, A. L., Ru, N., Dong, J., Stoica, G., Griffin, C. A., et al. (1994). Differential suppression of mammary and prostate cancer metastasis by human chromosomes 7 and 11. Cancer Research, 54, 6249–6256.PubMed
42.
Ichikawa, T., Ichikawa, Y., Dong, J., Hawkins, A. L., Griffin, C. A., Isaacs, W. B., et al. (1992). Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Research, 52, 3486–3490.PubMed
43.
Mashimo, T., Watabe, M., Cuthbert, A. P., Newbold, R. F., Rinker-Schaeffer, C. W., Helfer, E., et al. (1998). Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Research, 58, 4572–4576.PubMed
44.
Seraj, M. J., Harding, M. A., Gildea, J. J., Welch, D. R., & Theodorescu, D. (2001). The relationaship between BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human breast cancer cell lines. Clinical Experimental Metastasis, 18, 519–525.
45.
Shevde, L. A., Samant, R. S., Goldberg, S. F., Sikaneta, T., Alessandrini, A., Donahue, H. J., Mauger, D. T., & Welch, D. R. (2002). Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Experimental Cell Research, 273, 229–239.PubMed
46.
Smith, P. W., Liu, Y., Siefert, S. A., Moskaluk, C. A., Petroni, G. R., & Jones, D. R. (2009). Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small lung cancer. Cancer Letters, 276, 196–203.PubMed
47.
Zhang, S., Lin, Q. D., & Di, W. (2006). Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. International Journal of Gynecology and Cancer, 16, 522–531.
48.
Flolova, N., Edmonds, M. D., Bondenstine, T. M., Seitz, R., Johnson, M. R., Feng, R., Welch, D. R., & Frost, A. R. (2009). A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancer. Tumor Biology, 30, 148–159.
49.
Hicks, D. G., Yoder, B. J., Short, S., Tarr, S., Prescott, N., Crowe, J. P., Dawson, A. E., et al. (2006). Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer. Clinical Cancer Research, 12, 6702–6708.PubMed
50.
Dong, J. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Isaacs, J. T., & Barrett, J. C. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science, 268, 884–886.PubMed
51.
Yang, X. H., Welch, D. R., Phillips, K. K., Weissman, B. E., & Wei, L. L. (1997). KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Letters, 119, 149–155.PubMed
52.
Phillips, K. K., White, A. E., Hicks, D. J., Welch, D. R., Barrett, J. C., Wei, L. L., & Weissman, B. E. (1998). Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Molecular Carcinogenesis, 21, 111–120.PubMed
53.
Yang, X., Wei, L., Tang, C., Slack, R., Montgomory, E., & Lippman, M. (2000). KAI1 protein is downregulated during the progression of human breast cancer. Clinical Cancer Research, 6, 3424–3429.PubMed
54.
Liu, F. S., Dong, J. T., Chen, J. T., Hsieh, Y. T., Ho, E. S., & Hung, M. J. (2000). Frequent downregulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecologic Oncology, 78, 10–15.PubMed
55.
Lombardi, D. P., Geradts, J., Foley, J. F., Chiao, C., Lamb, P. W., & Barrett, J. C. (1999). Loss of KAI1 expression in the progression of colorectal cancer. Cancer Research, 59, 5724–5731.PubMed
56.
Goucharuk, V. N., del-Rosario, A., Kren, L., Anwar, S., Sheehan, C. E., Carlson, J. A., & Ross, J. S. (2004). Co-downregulation of PTEN, KAI-1 and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Annals of Diagnostic Pathology, 8, 6–16.
57.
Kim, H. L., Van der Griend, D. J., Yang, X., Benson, B. A., Dubauskas, Z., Yoshida, B. A., et al. (2001). Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostate cancers. Cancer Research, 61, 2833–2837.PubMed
58.
Cunningham, S. C., Kamanager, F., Kim, M. P., Hammoud, S., Haque, R., Lacobuzio-Donahue, C., et al. (2006). MKK4 status predicts survival after resection of gastric adenocarcinoma. Archives of Surgery, 141, 1095–1099.PubMed
59.
Stark, A. M., Tongers, K., Maass, N., Mehdorn, N. M., & Held-Feindt, J. (2004). Reduced metastasis-suppressor gene mRNA expression in breast cancer brain metastasis. Journal of Cancer Research and Clinical Oncology, 131, 191–198.PubMed
60.
Xin, W., Yun, K. J., Ricci, F., Zahurak, M., Qiu, W., Su, G. H., et al. (2004). MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunochemistry and relationship to disease course. Clinical Cancer Research, 10, 8516–8520.PubMed
61.
Yoshida, B. A., Dubauskas, Z., Chekmareva, M. A., Christiano, T. R., Stadler, W. M., & Rinker-Schaeffer, C. W. (1999). Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Research, 59(21), 5483–5487.PubMed
62.
Welch, D. R., Chen, P., Miele, M. E., McGary, C. T., Bower, J. M., Weissman, B. E., & Stanbridge, E. J. (1994). Microcell-mediated transfer to chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene, 9, 255–262.PubMed
63.
Lapatto, R., Pallais, J. C., Zhang, D., Chan, Y. M., Mahan, A., Cerrato, F., Le, W. W., Hoffman, G. E., & Seminara, S. B. (2007). Kiss1−/− mice exhibit more variable hypogonadism than Gpr54−/− mice. Endocrinology, 148, 4927–4936.PubMed
64.
Lee, J.-H., & Welch, D. R. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene KiSS-1. Cancer Research, 57, 2384–2387.PubMed
65.
Jiang, Y., Berk, M., Singh, L. H., Tan, H. Y., Yin, L. H., Powell, C. T., & Xu, Y. (2005). KiSS-1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clinical & Experimental Metastasis, 22, 369–376.
66.
McNally, L. R., Welch, D. R., Beck, B. H., Stafford, L. J., Long, J. W., Sellers, J. C., et al. (2010). KISS1 overexpression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clinical & Experimental Metastasis, 27(8), 591–600.
67.
Beck, B. H., & Welch, D. R. (2010). The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells. European Journal of Cancer, 46, 1283–1289.PubMed
68.
Dhar, D. K., Naora, H., Kubota, H., Maruyama, R., Yoshimura, H., Tonomoto, Y., et al. (2004). Downregulation of KiSS1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. International Journal of Cancer, 111, 868–872.
69.
Hata, K., Dhar, D. K., Watanabe, Y., Nakai, H., & Hoshiai, H. (2007). Expression of metastatin and a G protein coupled receptor (AXOR12) in epithelial ovarian cancer. European Journal of Cancer, 43, 1452–1459.PubMed
70.
Ikeguchi, M., Yamaguchi, K., & Kaibara, N. (2004). Clinical significance of the loss of KiSS1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in esophageal squamous cell carcinoma. Clinical Cancer Research, 10, 1379–1383.PubMed
71.
Katagiri, F., Nagai, K., Kida, A., Tomita, K., Oishi, S., Takeyama, M., et al. (2009). Clinical significance of plasma metastatin level in pancreatic cancer patients. Oncology Reports, 21, 815–819.PubMed
72.
Martin, T. A., Watkins, G., & Jiang, W. G. (2005). KISS1 expression in human breast cancer. Clinical & Experimental Metastasis, 22, 503–511.
73.
Prentice, L. M., Klausen, C., Kalloger, S., Kobel, M., McKinney, S., Santos, J. L., et al. (2007). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis of clear cell subtype in ovarian carcinoma. BMC Medicine, 5, 33.PubMed
74.
Shirasaki, F., Takada, M., Hatta, N., & Takehara, K. (2001). Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3–q23. Cancer Research, 61, 7422–7425.PubMed
75.
Steeg, P. S., Bevilacqua, G., Kopper, L., Thorgeirsson, U. P., Talmadge, J. E., Liotta, L. A., & Sobel, M. E. (1988). Evidence for a novel gene associated with low tumor metastatic potential. Journal of the National Cancer Institute, 80, 200–204.PubMed
76.
Lacombe, M. L., Milon, L., Munier, A., Mehus, J. G., & Lambeth, D. O. (2000). The human Nm23/nucleoside diphosphate kinases. Journal of Bioenergetics and Biomembranes, 32, 247–258.PubMed
77.
Marshall, J. C., Lee, J. H., & Steeg, P. S. (2009). Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. Molecular and Cellular Biochemistry, 329, 115–120.PubMed
78.
Steeg, P. S., & Theodorescu, D. (2007). Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology, 5, 206–219.
79.
Marshall, J. C., Collins, J., Marino, N., & Steeg, P. S. (2009). The Nm23-H1 metastasis suppressor as a translational target. European Journal of Cancer, 46, 1278–1282.
80.
Ouatas, T., Halverson, D., & Steeg, P. S. (2003). Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor expression in metastatic human breast cancer cells via glucocorticoid receptor-dependent, translational and post-transcriptional mechanisms: new use for old compounds. Clinical Cancer Research, 9, 3763–3772.PubMed
81.
Palmieri, D., Halverson, D. O., Ouatas, T., Horak, C. E., Salerno, M., Johnson, J., et al. (2005). Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. Journal of the National Cancer Institute, 97, 632–642.PubMed
82.
Kang, Y., Seigel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., Guise, T. A., & Massague, J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMed
83.
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massague, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436, 518–524.PubMed
84.
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., & Mssague, J. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 549, 1005–1009.
85.
Aslakson, C. J., & Miller, F. R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Research, 52, 1399–1405.PubMed
86.
Yang, J., Mani, S. A., Donaher, J. L., Ramaswarmy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927–939.PubMed
87.
Timar, J., Gyorffy, B., & Raso, E. (2010). Gene signatures of the metastatic potential of cutaneous melanoma: too much for too little? Clinical & Experimental Metastasis, 27, 371–387.
88.
Freeman, J. A., Tyler, D. S., Nevins, J. R., & Augustine, C. K. (2011). Use of gene expression and pathway signatures to characterize the complexity of human melanoma. The American Journal of Pathology, 178, 2513–2522.
89.
Ptitsyn, A. (2009). Computational analysis of gene expression space associated with Metastatic cancer. BMC Bioinformatics, 10, S6.PubMed
90.
Taylor, B. S., Varambally, S., & Chinnaiyan, A. (2006). A systems approach to model metastatic progression. Cancer Research, 66, 5537–5539.PubMed
91.
LaTulippe, E., Satagopan, J., Smith, A., Scher, H., Scardino, P., Reuter, V., & Gerald, W. L. (2002). Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Research, 62, 4499–4506.PubMed
92.
Bignotti, E., Tassi, R. A., Calza, S., Ravaggi, A., Bandiera, E., Rossi, E., et al. (2007). Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. American Journal of Obstetrics and Gynecology, 196, 245e1–245e11.
93.
Watanabe, T., Kobunai, T., Tanaka, T., Ishihara, S., Matsuda, K., & Nagawa, H. (2009). Gene expression signature and prediction of lymph node metastasis in colorectal cancer by DNA microarray. Diseases of the Colon & Rectum, 52, 1941–1948.
94.
Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, S., Dreezen, C., et al. (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Journal of Clinical Oncology, 29, 17–24.PubMed
95.
Inamura, K., & Ishikawa, Y. (2010). Lung cancer progression and metastasis from the prognostic point of view. Clinical & Experimental Metastasis, 27, 389–397.
96.
Winter, S. F., & Hunter, K. W. (2008). Mouse modifier genes in mammary tumorigenesis and metastasis. Journal of Mammary Gland Biology and Neoplasia, 13, 337–342.PubMed
97.
Hunter, K. W., & Alsarraj, J. (2009). Gene expression profiles and breast cancer metastasis: a genetic perspective. Clinical & Experimental Metastasis, 26, 497–503.
98.
Park, Y., Zhao, X., Lesueur, F., Lowy, D. R., Lancaster, M., Pharoah, P., Qian, X., & Hunter, K. W. (2005). Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nature Genetics, 37, 1055–1062.PubMed
99.
Crawford, N. P., Qian, X., Ziogas, A., Papageorge, A. G., Boersma, B. J., Walker, R. C., Lukes, L., Rowe, W. L., Zhang, J., Ambs, S., Lowy, D. R., Anton-Culver, H., & Hunter, K. W. (2007). Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics, 3, e214.PubMed
100.
Crawford, N. P., Alsarraj, J., Lukes, L., Walker, R. C., Officewala, J. S., Yang, H. H., et al. (2008). Bromodomain 4 activation predicts breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America, 105, 6380–6385.PubMed
101.
Gumireddy, K., Li, A., Gimotty, P. A., Klein-Szanto, A. J., Showe, L. C., Katsaros, D., Coukos, G., Zhang, L., & Huang, Q. (2009). KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nature Cell Biology, 11(11), 1297–1304.PubMed
102.
Gobeil, S., Zhu, X., Doillon, C. J., & Green, M. R. (2008). A genome-wide shRNA screen identified GAS1 as a novel metastasis suppressor gene. Genes & Development, 22, 2932–2940.
103.
Gumireddy, K., Sun, F., Klein-Szanto, A. J., Gibbins, G. M., Gimotty, P. A., Saunders, A. J., Schultz, P. G., & Huang, Q. (2007). An in vivo selection for metastasis promoting genes in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 104(16), 6696–6701.PubMed
104.
Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D. A., Li, A., Huang, G., Klein-Szanto, A. J., Gimotty, P. A., Katsaros, D., Coukos, G., Zhang, L., Puré, E., & Agami, R. (2008). The microRNAs miR-373 and miR-520c promote tumor invasion and metastasis. Nature Cell Biology, 10(2), 202–210.PubMed
105.
Gumireddy, K., & Huang, Q. (2010). Identification of metastasis genes by a functional genomics approach. Cell Cycle, 9(3), 423.PubMed
106.
Turajlic, S., Furney, S. J., Lambros, M. B., Mitsopoulos, C., Kozarewa, I., Geyer, F. C., et al. (2011). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Research. doi:10.​1101/​gr.​125529.​111.
107.
Kabbarah, O., Nogueira, C., Feng, B., Nazarian, R. M., Bosenberg, M., Wu, M., et al. (2010). Integrative genome comparison of primary and metastatic melanomas. PLoS One, 5, e10770.PubMed
108.
Vermaat, J. S., Nijman, I. J., Koudijs, M. J., Gerritse, F. L., Scherer, S. J., Mokry, M., et al. (2011). Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clinical Cancer Research. doi:10.​1158/​1078-0432.​CCR-11-1965.
109.
Sayagues, J. M., Fontanillo, C., del Mar Abad, M., Gonzales-Gonzales, M., Saraquete, M. E., del Carmon Chillon, M., et al. (2010). Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays. PLoS One, 5, e13752.PubMed
110.
Ghadimi, B. M., Grade, M., Monkemeyer, C., Kulle, B., Gaedcke, J., Gunawan, B., et al. (2006). Distinct chromosomal profiles in metastasizing and non-metastasizing colorectal carcinomas. Cellular Oncology, 28, 273–281.PubMed
111.
Al-Mulla, F., AlFadhili, S., Al-Hakim, A. H., Going, J. J., & Bitar, M. S. (2006). Metastatic recurrence of early stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q. Journal of Clinical Pathology, 59, 624–630.PubMed
112.
Macintosh, C. A., Stower, M., Reid, N., & Maitland, N. J. (1998). Precise of microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Research, 58, 23–28.PubMed
113.
Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., et al. (2009). Copy Number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 15, 559–565.PubMed
114.
Robbins, C. M., Tembe, W. A., Baker, A., Sinari, S., Moses, T. Y., Beckstrom-Sternberg, S., et al. (2011). Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Research, 21, 47–55.PubMed
115.
Holcomb, I. N., Young, J. M., Coleman, I. M., Sarali, K., Grove, D. I., Hsu, L., et al. (2009). Comparative analysis of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Research, 69, 7793–7802.PubMed
116.
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., et al. (2009). Intergrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11–22.
117.
Kumar, A., White, T. A., MacKenzie, A. P., Clegg, N., Lee, C., Dumpit, R. F., et al. (2011). Exome sequencing identified a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proceedings of the National Academy of Sciences of the United States of America, 108, 17087–17092.PubMed
118.
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109–1113.PubMed
119.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distance metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467, 1114–1117.PubMed
120.
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., et al. (2010). Genome remodeling in a basal-like breast cancer metastasis and xenograft. Nature, 464, 999–1005.PubMed
121.
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., et al. (2009). Mutational evolution in a lobular breast tumor profiled at single nucleotide resolution. Nature, 461, 809–813.PubMed
Metadaten
Titel
Genomics screens for metastasis genes
verfasst von
Jinchun Yan
Qihong Huang
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 3-4/2012
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9362-z

Weitere Artikel der Ausgabe 3-4/2012

Cancer and Metastasis Reviews 3-4/2012 Zur Ausgabe

NON-THEMATIC REVIEW

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

OriginalPaper

Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene

OriginalPaper

MicroRNA control of epithelial–mesenchymal transition and metastasis

OriginalPaper

Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes

OriginalPaper

Non-glucose metabolism in cancer cells—is it all in the fat?

OriginalPaper

Raf kinase inhibitor protein (RKIP) in cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise